Company* (Country; Symbol)

Company* (Country; Symbol)

Change from original agreement

Terms/Details (Date)

Cellegy Pharmaceuticals Inc. (CLGY)

ProStrakan Group plc (UK; LSE:PSK)

They renegotiated deal under which ProStrakan distributes Rectogesic in Europe

ProStrakan will assume support responsibility, and purchase product directly from the manufacturer; Cellegy gets $2M and up to $0.75M in milestone payments (11/10)

Crucell NV (the Netherlands; CRXL)

Ark Therapeutics Group plc (UK; LSE:AKT)

Ark renewed its its PER.C6 technology licensing agreement

Ark got research and commercial rights to develop and manufacture gene-based drugs using the technology; terms were not disclosed (1/18)

Third Wave Technologies Inc. (TWTI)

Digene Corp. (DIGE)

Third Wave dismissed a lawsuit against Digene over patents related to human papilloma-virus

The agreement does not include the grant of any license, nor does it include payments by either company (1/13)


Micromet AG* (Germany)

Enzon Pharmaceuticals Inc. (ENZN)

They ended a deal to identify and develop antibody-based drugs for treating inflammatory and autoimmune diseases

They had combined technology in single-chain antibodies in the April 2002 collaboration; Micromet gets rights to the lead candidate (MT203) generated in the deal, and Enzon would get royalties; cross-license and marketing agreements between the companies remained unchanged (11/28)


* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange.

No Comments